Literature DB >> 9951684

New p53-based anti-cancer therapeutic strategies.

K G Wiman1.   

Abstract

The p53 gene is frequently mutated in human tumours and therefore an important target for therapeutic intervention. Several p53-based strategies for treatment of cancer are currently under development. p53 gene therapy has resulted in tumour regression in patients with lung cancer. A mutant adenovirus can obliterate tumour cells carrying mutant p53 or lacking p53, but is unable to replicate in normal cells. Furthermore, current studies suggest that reactivation of mutant p53 proteins in tumours using small p53-activating molecules may initiate p53-dependent apoptosis and thus eliminate the tumour.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9951684     DOI: 10.1007/BF02787204

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  49 in total

1.  Regulation of the specific DNA binding function of p53.

Authors:  T R Hupp; D W Meek; C A Midgley; D P Lane
Journal:  Cell       Date:  1992-11-27       Impact factor: 41.582

2.  Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases.

Authors:  I Takenaka; F Morin; B R Seizinger; N Kley
Journal:  J Biol Chem       Date:  1995-03-10       Impact factor: 5.157

3.  Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression.

Authors:  L B Owen-Schaub; W Zhang; J C Cusack; L S Angelo; S M Santee; T Fujiwara; J A Roth; A B Deisseroth; W W Zhang; E Kruzel
Journal:  Mol Cell Biol       Date:  1995-06       Impact factor: 4.272

4.  Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor.

Authors:  R Eckner; M E Ewen; D Newsome; M Gerdes; J A DeCaprio; J B Lawrence; D M Livingston
Journal:  Genes Dev       Date:  1994-04-15       Impact factor: 11.361

5.  Small peptides activate the latent sequence-specific DNA binding function of p53.

Authors:  T R Hupp; A Sparks; D P Lane
Journal:  Cell       Date:  1995-10-20       Impact factor: 41.582

6.  p53-mediated apoptosis in HeLa cells can be overcome by excess pRB.

Authors:  Y Haupt; S Rowan; M Oren
Journal:  Oncogene       Date:  1995-04-20       Impact factor: 9.867

7.  Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein.

Authors:  P R Yew; A J Berk
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

8.  Bax-deficient mice with lymphoid hyperplasia and male germ cell death.

Authors:  C M Knudson; K S Tung; W G Tourtellotte; G A Brown; S J Korsmeyer
Journal:  Science       Date:  1995-10-06       Impact factor: 47.728

9.  Induction of the growth inhibitor IGF-binding protein 3 by p53.

Authors:  L Buckbinder; R Talbott; S Velasco-Miguel; I Takenaka; B Faha; B R Seizinger; N Kley
Journal:  Nature       Date:  1995-10-19       Impact factor: 49.962

10.  Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53.

Authors:  P Abarzúa; J E LoSardo; M L Gubler; A Neri
Journal:  Cancer Res       Date:  1995-08-15       Impact factor: 12.701

View more
  1 in total

1.  Carcinogenesis and cancer prevention: the process and the disease deserve a better understanding.

Authors:  Gopala Kovvali
Journal:  J Carcinog       Date:  2002-11-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.